Posted by Michael Wonder on 27 Jul 2023
British Columbia to publicly reimburse Albrioza for the treatment of ALS
19 July 2023 - Amylyx Pharmaceuticals Canada announced today that the Company has entered into a Product Listing Agreement with British Columbia for the public reimbursement of Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) through British Columbia's PharmaCare, effective 19 July 2023.
In the CENTAUR clinical trial, Albrioza demonstrated a significant reduction in disease progression and functional decline among individuals diagnosed with amyotrophic lateral sclerosis.
